A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors
← catalyst calendarSponsored by Incyte Corporation (industry) · INCY — their whole pipeline →.
Phase
Phase 1/2
Status
Terminated
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
5actual
Sites
6
Country
United Kingdom
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
This was a strategic business decision. There were no safety concerns contributing to this decision.
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-04-16 | actual | When the study began enrolling |
| Primary completion | 2025-06-06 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-06-06 | actual | The whole study's end, after follow-up |
| First posted | 2023-07-18 | actual | When this record first appeared on the registry |
| Results posted | 2026-06-04 | actual | When the sponsor posted results to the registry |
| Record updated | 2026-06-04 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Advanced Solid Tumors
Interventions
- Drug: INCB099280
- Drug: axitinib
Primary outcomes
what the primary-completion date above is the date OFPart 1: Number of Participants With Dose-limiting Toxicities (DLTs)
measured up to 3 weeks
Part 1: Number of Participants With Any Treatment-emergent Adverse Event (TEAE)
measured up to approximately 1 year
Part 1: Number of Participants With TEAEs Leading to a Dosing Modification (Treatment Interruption, Dose Reduction, and Permanent Discontinuation of Either Study Drug)
measured up to approximately 1 year
Part 2: Objective Response
measured up to 2 years
Posted documents
hosted by the registry — we link, never re-serveStudy Protocolposted 2024-04-04 · 1.3 MB · Prot_000.pdf
Statistical Analysis Planposted 2025-06-25 · 412 KB · SAP_001.pdf
Permalink · INCY's whole pipeline · Catalyst calendar · Every registered study · What changed